Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG MDNA11
- DRUG Pembrolizumab (KEYTRUDA®)
Study Locations (20)
Other
- Mater Misericordiae University Hospital — Dublin
- START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria — Lisbon
- Instituto Portugues De Oncologia Do Porto — Porto
- Institut Catala d'Oncologia (ICO)-Badalona — Badalona
California
- Sharp Memorial Hospital — San Diego
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco
- Providence Saint John's Health Center — Santa Monica
New South Wales
- Scientia Clinical Research — Randwick
- Macquarie University — Sydney
Queensland
- University of the Sunshine Coast — Buderim
- Gallipoli Medical Research Foundation — Greenslopes
Gyeonggi-do
- Seoul National University Bundang Hospital — Seongnam-si
- The Catholic University of Korea St. Vincent Hospital — Suwon
Florida
- Boca Raton Regional Hospital — Boca Raton
Georgia
- Emory - Winship Cancer Institute — Atlanta
Michigan
- Karmanos Cancer Institute — Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05086692
The ClinicalTrials.gov registry entry for NCT05086692 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicenna Therapeutics, which has 28 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions — of which MDNA11 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05086692 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, California, New South Wales. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05086692 about?
NCT05086692 is a clinical study titled "A Beta-only IL-2 ImmunoTherapY Study". This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
What is the current status of trial NCT05086692?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2021-08-27. Estimated completion is 2026-12-30.
What conditions does trial NCT05086692 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Gastric Cancer, Cervical Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05086692?
The interventions under investigation include: MDNA11 (DRUG), Pembrolizumab (KEYTRUDA®) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05086692?
This trial is sponsored by Medicenna Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05086692 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.